BLU-5937 remains in development and has not been approved for commercialization. The clinical safety and effectiveness of BLU-5937 have not yet been fully established. The development of this product, and an investment in BELLUS Health common shares, involved a significant amount of risks. We invite you to review our Annual Information Form to learn more about these risks factors. A summary of these can also be reviewed here.